A Trial to Learn How Much Rivaroxaban Gets Into the Blood When Taken in Different Forms and How Safe They Are in Healthy Men
Study Details
Study Description
Brief Summary
Researchers are looking for a better way to treat venous thromboembolic disease, also known as VTE. In people with VTE, blood clots form in the veins of the legs, groin, or arms. These clots or a piece of a clot can break free and move around the body in the blood vessels. These clots can block small blood vessels, causing other conditions like high blood pressure, heart attack, and stroke.
Before people with a medical condition can take an approved treatment in a new form, researchers do trials in healthy participants. This helps them understand how the new form acts in the body and to better understand its safety.
In this trial, the researchers will compare how much of the trial treatment gets into the blood when taken in 2 different forms in a small number of participants. The trial will include about 30 men who are aged 18 to 55.
In this trial, there will be 2 groups of participants. The participants will take rivaroxaban in the current tablet form and in a new liquid form 1 time. This was a "crossover" trial. In a crossover trial, all the participants will take both forms of the treatments, but in a different order.
During the trial, the participants will stay at their trial site 2 times for 5 days. But, the participants can be in the trial for up to about 6 weeks. During the trial, the doctors will take blood and urine samples and check the participants' heart health using an electrocardiogram (ECG) and measure the blood pressure. The participants will also answer questions about how they are feeling, if they have any medical problems, and about any medications they are taking.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Treatment A: Single oral dose of a 20 mg tablet rivaroxaban 2-way crossover: The subjects will receive the following treatments in a randomized order: Treatment A: Single oral dose of a 20 mg tablet rivaroxaban, administered under fed conditions Treatment B: Single oral dose of 20 mg rivaroxaban, granules for oral suspension administered under fed conditions. |
Drug: 20 mg tablet rivaroxaban
Single oral dose of a 20 mg tablet rivaroxaban, administered under fed conditions
|
| Experimental: Treatment B: Single oral dose of 20 mg rivaroxaban, granules 2-way crossover: The subjects will receive the following treatments in a randomized order: Treatment A: Single oral dose of a 20 mg tablet rivaroxaban, administered under fed conditions Treatment B: Single oral dose of 20 mg rivaroxaban, granules for oral suspension administered under fed conditions. |
Drug: 20 mg rivaroxaban, granules for oral suspension
Single oral dose of 20 mg rivaroxaban, granules for oral suspension administered under fed conditions.
|
Outcome Measures
Primary Outcome Measures
- AUC of rivaroxaban granules for oral suspension vs. rivaroxaban tablet [From pre-dose up to 72 hours after drug administration]
AUC = area under the concentration vs. time curve from zero to infinity after single (first) dose Rivaroxaban Blood sampling for rivaroxaban pharmacokinetics in plasma.
- AUC(0-tlast) of rivaroxaban granules for oral suspension vs. rivaroxaban tablet [From pre-dose up to 72 hours after drug administration]
AUC(0-tlast) = AUC from time 0 to the last data point > lower limit of quantification (LLOQ) Rivaroxaban Blood sampling for rivaroxaban pharmacokinetics in plasma.
- Cmax of rivaroxaban granules for oral suspension vs. rivaroxaban tablet [From pre-dose up to 72 hours after drug administration.]
Cmax = maximum observed drug concentration in measured matrix after single dose administration Rivaroxaban Blood sampling for rivaroxaban pharmacokinetics in plasma.
Secondary Outcome Measures
- Number of treatment-emergent adverse events [Up to 7-14 days after the last administration]
Adverse events occurring in the period between the signing of the informed consent and the end of the follow-up phase.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Healthy male subjects.
-
Age: 18 to 55 years (inclusive) at the screening examination/visit.
-
Race: White (Note: Clinical Data Interchange Standards Consortium definition of White: Denotes a person with European, Middle Eastern, or North African ancestral origin who identifies, or is identified, as White (Food and Drug Administration [FDA]).
-
Body mass index (BMI): above/equal 18 and below/equal 29.9 kg/m2.
-
Ability to understand and follow instructions.
Exclusion Criteria:
-
Pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal
-
Known or suspected liver disorders and bile secretion/flow
-
Subjects with thyroid disorders as evidenced by assessment of thyroid stimulating hormone (TSH) levels outside the normal reference range at screening
-
Personal or familial history of genetically muscular diseases
-
Known hypersensitivity to the study drugs (active substances or excipients of the preparations)
-
Known severe allergies e.g. allergies to more than 3 allergens, allergies affecting the lower respiratory tract- allergic asthma, allergies requiring therapy with corticosteroids, urticaria) or significant non-allergic drug reactions
-
Known disorders with increased bleeding risk (e.g., periodontosis, hemorrhoids, acute gastritis, peptic ulcer)
-
Known sensitivity to common causes of bleeding (e.g. nasal)
-
Clinically relevant findings in the electrocardiogram (ECG) such as a second- or third-degree atrioventricular (AV) block, prolongation of the QRS (QRS interval in ECG) complex over 120 msec or of the QTc-interval over 450 msec at the first screening visit
-
Presence or history of arrhythmic disturbances; or known congenital QT (QT interval in ECG) prolongation
-
Systolic blood pressure below 100 or above 140 mmHg
-
Diastolic blood pressure below 50 or above 90 mmHg
-
Heart rate below 50 or above 90 beats/ min
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CRS Clinical-Research-Services Mönchengladbach GmbH | Mönchengladbach | Nordrhein-Westfalen | Germany | 41061 |
Sponsors and Collaborators
- Bayer
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 19366
- 2017-000609-18